Literature DB >> 9544918

Recurrent group B streptococcal disease in infants: Who should receive rifampin?

J T Atkins1, G P Heresi, T M Coque, C J Baker.   

Abstract

A preterm breast-fed infant had three episodes of type Ia/c group B streptococcus septicemia. After the second episode rifampin was given to the infant, but further Ia/c exposure to maternal breast milk ensued. We propose rifampin treatment for both the mother and infant in cases of recurrent group B streptococcus disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544918     DOI: 10.1016/s0022-3476(98)70037-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Three distinct episodes of GBS septicemia in a healthy newborn during the first month of life.

Authors:  Hanna Soukka; Kaisu Rantakokko-Jalava; Susanna Vähäkuopus; Olli Ruuskanen
Journal:  Eur J Pediatr       Date:  2010-03-25       Impact factor: 3.183

2.  Neonatal group B streptococcal disease associated with infected breast milk.

Authors:  W J Olver; D W Bond; T C Boswell; S L Watkin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

3.  Horizontal transmission of group B streptococcus in a neonatal intensive care unit.

Authors:  Julia Morinis; Jay Shah; Prashanth Murthy; Martha Fulford
Journal:  Paediatr Child Health       Date:  2011-06       Impact factor: 2.253

4.  Group B streptococcal disease in infants in the first year of life: a nationwide surveillance study in Japan, 2011-2015.

Authors:  Kousaku Matsubara; Kiyoshi Hoshina; Masatoshi Kondo; Isao Miyairi; Yoshiya Yukitake; Yusuke Ito; Kisei Minami; Ryuichi Genkawa
Journal:  Infection       Date:  2017-02-25       Impact factor: 3.553

5.  Infected breast milk associated with late-onset and recurrent group B streptococcal infection in neonatal twins: a genetic analysis.

Authors:  Arnaud Gagneur; Geneviève Héry-Arnaud; Séverine Croly-Labourdette; Gisèle Gremmo-Feger; Sophie Vallet; Jacques Sizun; Roland Quentin; Didier Tandé
Journal:  Eur J Pediatr       Date:  2008-12-16       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.